Stereotactic Body Radiotherapy for the Management of Early-Stage Non–Small-Cell Lung Cancer: A Clinical Overview

Buchberger, D.S.; Videtic, Gregory M.M.

doi:10.1200/op.22.00475

Cited by 15 publications

(6 citation statements)

References 80 publications

(134 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is a prevalent and deadly malignancy worldwide, with non‐small cell lung cancer (NSCLC) is the most common histological type of lung cancer, accounting for 85%. 24 , 25 In China, lung cancer is the most common cancer and the leading cause of cancer‐related deaths. 24 , 25 Unfortunately, NSCLC is often diagnosed in advanced stages, leading to poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

TRIM11 promotes cell proliferation of non‐small cell lung cancer through the inhibition of ferroptosis by AMPK

Liang,

Li,

Zhang

et al. 2023

Clinical Respiratory J

View full text Add to dashboard Cite

Lung cancer is one of the leading causes of cancer‐related deaths worldwide, with non‐small cell lung cancer (NSCLC) being the most prevalent type. This study investigates the role of TRIM11 gene in NSCLC and its underlying mechanism. NSCLC patients were recruited from our hospital and showed upregulated TRIM11 mRNA and protein expressions. Patients with high TRIM11 expression had lower survival rates. TRIM11 gene was found to promote cell proliferation and reduce ROS‐induced ferroptosis in NSCLC. Additionally, TRIM11 gene induced AMPK expression and its regulation affected TRIM11's effects on cell proliferation and ferroptosis in NSCLC. IP analysis revealed that TRIM11 protein interacted with AMPK protein in NSCLC. These data confirmed that TRIM11 promotes cell proliferation and reduces ROS‐induced ferroptosis in NSCLC through AMPK. Hence, TRIM11 is a potential target for the treatment of NSCLC and other cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

TRIM11 promotes cell proliferation of non‐small cell lung cancer through the inhibition of ferroptosis by AMPK

Liang,

Li,

Zhang

et al. 2023

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…To investigate the potential induction of early-stage lung brosis and the shaping of a pro-tumorigenic lung microenvironment following chest irradiation, mouse models were established. The chest area of mice received radiation within a speci ed region (1.5 cm × 1 cm), mimicking the dosage used in clinical stereotactic body radiotherapy 22 (Supplementary Fig. S1).…”

Section: Formation Of Pro-tumorigenic Lung Microenvironment Following...mentioning

confidence: 99%

Prevention of radiotherapy-induced pro-tumorigenic microenvironment by SFK-inhibitors

Kang,

Choi,

Kim

et al. 2024

Preprint

View full text Add to dashboard Cite

Radiotherapy is a widely employed technique for eradication of tumor using high-energy beams, and has been applied to approximately 50% of all solid tumor patients. However, its non-specific, cell-killing property leads to inevitable damage to surrounding normal tissues. Recent findings suggest that radiotherapy-induced tissue damage contributes to the formation of a pro-tumorigenic microenvironment. Here, we utilized mouse models to uncover the mechanisms underlying the development of such a radiation-triggered microenvironment. Radiotherapy-induced tissue damage stimulates infiltration of monocyte-derived macrophages and their differentiation into M2 macrophages, ultimately leading to fibrosis and the formation of a pro-tumorigenic microenvironment. This phenomenon was consistently observed across two mouse strains and two organ-targeted radiotherapy models. Notably, SRC family kinases (SFKs) emerged as crucial factors in the formation of the radiotherapy-induced pro-tumorigenic microenvironment. SFKs activation in epithelial cells and fibroblasts was triggered by direct exposure to irradiation or M2 macrophage cytokines. Remarkably, the administration of SFK-targeted inhibitors reversed myofibroblast activation, effectively ameliorating fibrosis and the pro-tumorigenic microenvironment in radiated tissues. Further, combined administration of radiotherapy and SFK-targeted inhibitors significantly enhanced the survival of tumor-bearing mice. In conclusion, reshaping of the tissue microenvironment by SFK-targeting is a potential strategy for prevention of metastasis and recurrence following radiotherapy.

show abstract

“…Despite the good local control rates, locoregional therapies face a persistent challenge of newly emerging metastases distant from the site of intervention [27]. Despite these challenges, lung ablation is well tolerated, and has minimal impact in lung function allowing re-treatment [11,39,52,65]. In contrast, surgery is associated with higher complication rates, decline in lung function, and increased technical complexity for subsequent interventions within the same lung [23,49,53,54].…”

Section: Clinical Outcome Of Thermal Ablation Vs Metastasectomy and R...mentioning

confidence: 99%

“…SBRT is the standard treatment for inoperable early-stage lung cancer patients [7], providing a comparable overall survival, local disease control rate, and a preserved quality of life while having a significantly lower rate of complications, including radiation pneumonitis and postradiation dyspnea when compared with conventional fractionated external beam radiotherapy (EBRT) [11][12][13][14][15]. Nevertheless, irradiation-related toxicities such as pneumonitis and chest wall toxicity can occur in 20% and 46%, respectively [14,16].…”

Section: Introductionmentioning

confidence: 99%

Treatment strategies for malignant pulmonary nodule: beyond lobectomy. Point-counterpoint

Chang,

Ng,

Nezami

2023

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review Technological advancement in low-dose computed tomography resulted in an increased incidental discovery of early-stage lung cancer and multifocal ground glass opacity. The demand for parenchyma-preserving treatment strategies is greater now than ever. Pulmonary ablative therapy is a groundbreaking technique to offer local ablative treatment in a lung-sparing manner. It has become a promising technique in lung cancer management with its diverse applicability. In this article, we will review the current development of ablative therapy in lung and look into the future of this innovative technique. Recent findings Current literature suggests that ablative therapy offers comparable local disease control to other local therapies and stereotactic body radiation therapy (SBRT), with a low risk of complications. In particular, bronchoscopic microwave ablation (BMWA) has considerably fewer pleural-based complications due to the avoidance of pleural puncture. BMWA can be considered in the multidisciplinary treatment pathway as it allows re-ablation and allows SBRT after BMWA. Summary With the benefits which ablative therapy offers and its ability to incorporate into the multidisciplinary management pathway, we foresee ablative therapy, especially BMWA gaining significance in lung cancer treatment. Future directions on developing novel automated navigation platforms and the latest form of ablative energy would further enhance clinical outcomes for our patients.

show abstract

Stereotactic Body Radiotherapy for the Management of Early-Stage Non–Small-Cell Lung Cancer: A Clinical Overview

Cited by 15 publications

References 80 publications

TRIM11 promotes cell proliferation of non‐small cell lung cancer through the inhibition of ferroptosis by AMPK

TRIM11 promotes cell proliferation of non‐small cell lung cancer through the inhibition of ferroptosis by AMPK

Prevention of radiotherapy-induced pro-tumorigenic microenvironment by SFK-inhibitors

Treatment strategies for malignant pulmonary nodule: beyond lobectomy. Point-counterpoint

Contact Info

Product

Resources

About